Dysregulated atrial gene expression of osteoprotegerin/ receptor activator of nuclear factor-κB (RANK)/ RANK ligand axis in the development and progression of atrial fibrillation

Circulation Journal

Volumn 75, Issue 12, 2011, Pages 2781-2788

  Cao, Hailong ^a   Wang, Jian ^c   Xi, Lei ^b   Røe, Oluf Dimitri ^b,d   Chen, Yijiang ^b   Wang, Dongjin ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c YIXING PEOPLE S HOSPITAL   (China)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atrial fibrillation; Atrial structural remodeling; Osteoprotegerin; Receptor activator of nuclear factor B; Receptor activator of nuclear factor b ligand

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; MALE; MITRAL VALVE; NUCLEOTIDE SEQUENCE; OSTEOPROTEGERIN GENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B GENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND GENE; SINUS RHYTHM; UPREGULATION;

ADULT; ATRIAL FIBRILLATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HEART ATRIA; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82455210529     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0795     Document Type: Article

References (35)

1. Inoue H. Antithrombotic therapy: ESC guidelines vs JCS guidelines. Circ J 2010; 74: 2542-2545.
2. Chang D, Zhang S, Yang D, Gao L, Lin Y, Chu Z, et al. Effect of epicardial fat pad ablation on acute atrial electrical remodeling and inducibility of atrial fibrillation. Circ J 2010; 74: 885-894.
3. Knecht S, Wilton SB, Haïssaguerre M. The 2010 update of the ESC guidelines for the management of atrial fibrillation. Circ J 2010; 74: 2534-2537.
4. Ko WC, Hong CY, Hou SM, Lin CH, Ong ET, Lee CF, et al. Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. Circ J 2011; 75: 1592-1600.
5. Aimé-Sempé C, Folliguet T, Rücker-Martin C, Krajewska M, Krajewska S, Heimburger M, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999; 34: 1577-1586.
6. Hagiwara N. Inflammation and atrial fibrillation. Circ J 2010; 74: 246-247.
7. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
8. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011; 60: 2187-2196.
9. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111: 3119-3125.
10. Steinmetz M, Skowasch D, Wernert N, Welsch U, Preusse CJ, Welz A, et al. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 2008; 17: 187-193.
11. Halapas A, Zacharoulis A, Theocharis S, Karavidas A, Korres D, Papadopoulos K, et al. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. Clin Chem Lab Med 2008; 46: 510-516.
12. Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, et al. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol 2006; 177: 3799-3805.
13. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004; 52: 821-831.
14. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
15. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461-2468.
16. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009; 104: 92-96.
17. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60: 315-325.
18. Kim NH, Ahn Y, Oh SK, Cho JK, Park HW, Kim YS, et al. Altered patterns of gene expression in response to chronic atrial fibrillation. Int Heart J 2005; 46: 383-395.
19. Cao H, Xue L, Xu X, Wu Y, Zhu J, Chen L, et al. Heat shock proteins in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cell Stress Chaperones 2011; 16: 517-528.
20. Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 2006; 42: 415-420.
21. Osmancik P, Peroutka Z, Budera P, Herman D, Stros P, Straka Z, et al. Decreased apoptosis following successful ablation of atrial fibrillation. Cardiology 2010; 116: 302-307.
22. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-20962.
23. Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Tanaka F, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 2004; 137: 430-436.
24. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-379.
25. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004; 109: 363-368.
26. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530.
27. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004; 43: 818-825.
28. Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1076-1082.
29. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Stroud RE, et al. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 2008; 10: 125-128.
30. Feng W, Li W, Liu W, Wang F, Li Y, Yan W. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 2009; 87: 212-218.
31. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43: 292-297.
32. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
33. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANK-L and osteoprotegerin. Circ Res 2004; 95: 1046-1057.
34. Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 2004; 50: 2309-2316.
35. Ho TY, Santora K, Chen JC, Frankshun AL, Bagnell CA. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant- induced arthritis. Bone 2011; 48: 1346-1353.